- $561.64m
- $263.96m
- 39
- 23
- 76
- 43
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.74 | ||
| Price to Tang. Book | 1.74 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -42.19% | ||
| Return on Equity | -37.6% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.
Directors
- Jonathan Lim CHM (49)
- David Chacko CFO (39)
- Michael Varney CEX (63)
- Lisa Tesvich-bonora CHO
- Brian Baker SVF
- Nik Chetwyn SVP
- Chandra Lovejoy SVP
- Robert Shoemaker SVP
- David Luo VOP
- Bao Truong VPR
- Minli Xie VPR
- Dawei Xuan VPR
- Jing Yi VPR
- Rachel Cervantes VBD
- Ebun Garner GCN (49)
- Wei Lin EXO (52)
- James Bristol IND (74)
- Alexander Casdin IND (53)
- Bihua Chen IND (53)
- Julie Hambleton IND (63)
- Valerie Harding-Start IND (62)
- Pratik Multani IND (54)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- July 2nd, 2018
- Public Since
- July 15th, 2021
- No. of Shareholders
- 55
- No. of Employees
- 126
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 237,983,624
- Address
- 10835 Road To The Cure, Suite 140, SAN DIEGO, 92121-1130
- Web
- https://www.erasca.com/
- Phone
- +1 8584656511
- Auditors
- KPMG LLP
Upcoming Events for ERAS
Similar to ERAS
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 20:33 UTC, shares in Erasca are trading at $2.11. This share price information is delayed by 15 minutes.
Shares in Erasca last closed at $2.11 and the price had moved by -20.68% over the past 365 days. In terms of relative price strength the Erasca share price has underperformed the S&P500 Index by -36.88% over the past year.
The overall consensus recommendation for Erasca is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Erasca does not currently pay a dividend.
Erasca does not currently pay a dividend.
Erasca does not currently pay a dividend.
To buy shares in Erasca you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.11, shares in Erasca had a market capitalisation of $502.15m.
Here are the trading details for Erasca:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ERAS
Based on an overall assessment of its quality, value and momentum Erasca is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Erasca is $4.57. That is 116.59% above the last closing price of $2.11.
Analysts covering Erasca currently have a consensus Earnings Per Share (EPS) forecast of -$0.77 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Erasca. Over the past six months, its share price has underperformed the S&P500 Index by -12.62%.
As of the last closing price of $2.11, shares in Erasca were trading -0.14% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Erasca PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.11.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Erasca's management team is headed by:
- Jonathan Lim - CHM
- David Chacko - CFO
- Michael Varney - CEX
- Lisa Tesvich-bonora - CHO
- Brian Baker - SVF
- Nik Chetwyn - SVP
- Chandra Lovejoy - SVP
- Robert Shoemaker - SVP
- David Luo - VOP
- Bao Truong - VPR
- Minli Xie - VPR
- Dawei Xuan - VPR
- Jing Yi - VPR
- Rachel Cervantes - VBD
- Ebun Garner - GCN
- Wei Lin - EXO
- James Bristol - IND
- Alexander Casdin - IND
- Bihua Chen - IND
- Julie Hambleton - IND
- Valerie Harding-Start - IND
- Pratik Multani - IND